Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′- O -Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

Author： Yu Rosie Z.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.48, Iss.1, 2009-01, pp. : 39-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lack of Pharmacokinetic Interaction for ISIS 113715, a 2′- 0 -Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone

By Geary Richard S.  

Clinical Pharmacokinetics, Vol. 45, Iss. 8, 2006-01 ,pp. : 789-801

Adis International

Access to resources Recommend Favorite

Apolipoprotein B Antisense Inhibition -Update on Mipomersen

By  

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3132-3142

Bentham Science Publishers

Access to resources Recommend Favorite

Ezetimibe–Simvastatin, a pharmacodynamic interaction?

By Lozano Roberto   Marin Reyes   Santacruz M-Jesus   Freire Isabel  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 3, 2013-02 ,pp. : 359-360

Informa Healthcare

Access to resources Recommend Favorite

Amiodarone/ezetimibe/simvastatin interaction: Rhabdomyolysis: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1221, 2008-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Killing the Messenger: Antisense DNA and siRNA

By  

Current Drug Targets, Vol. 5, Iss. 8, 2004-11 ,pp. : 683-689

Bentham Science Publishers

Access to resources Recommend Favorite